Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors

• Published in: Acta pharmaceutica Sinica. B Vol. 11; no. 3; pp. 781 - 794
• Main Authors: Wu, Xiaowei, Dai, Mengdi, Cui, Rongrong, Wang, Yulan, Li, Chunpu, Peng, Xia, Zhao, Jihui, Wang, Bao, Dai, Yang, Feng, Dan, Yang, Tianbiao, Jiang, Hualiang, Geng, Meiyu, Ai, Jing, Zheng, Mingyue, Liu, Hong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2021; Elsevier
• Subjects: Antitumor efficacy; Covalent FGFR inhibitors; Original; Pyrazolo[3,4-d]pyridazinone; Structure−activity relationships; Tyrosine kinase; Virtual screening; Structure−activity relationships; CADD; SAR; Virtual screening; PLCγ; MAPK; RTKs; Antitumor efficacy; FGFR; EGFR; Tyrosine kinase; Covalent FGFR inhibitors; Pyrazolo[3,4-d]pyridazinone; PI3K; BTK; PK; GSH; FGFR, fibroblast growth factor receptor; PLCγ, phospholipase Cγ; SAR, structure−activity relationship; GSH, glutathione; PI3K, phosphoinositide 3-kinase; EGFR, epidermal growth factor receptor; BTK, brutons tyrosine kinase; CADD, computer-aided drug design; RTKs, receptor tyrosine kinases; PK, pharmacokinetics; MAPK, mitogen-activated protein kinase
• DOI: 10.1016/j.apsb.2020.09.002
• ISSN: 2211-3835

Fibroblast growth factor receptors (FGFRs) have emerged as promising targets for anticancer therapy. In this study, we synthesized and evaluated the biological activity of 66 pyrazolo[3,4-d]pyridazinone derivatives. Kinase inhibition, cell proliferation, and whole blood stability assays were used to evaluate their activity on FGFR, allowing us to explore structure−activity relationships and thus to gain understanding of the structural requirements to modulate covalent inhibitors’ selectivity and reactivity. Among them, compound 10h exhibited potent enzymatic activity against FGFR and remarkably inhibited proliferation of various cancer cells associated with FGFR dysregulation, and suppressed FGFR signaling pathway in cancer cells by the immunoblot analysis. Moreover, 10h displayed highly potent antitumor efficacy (TGI = 91.6%, at a dose of 50 mg/kg) in the FGFR1-amplified NCI-H1581 xenograft model. A series of pyrazolo[3,4-d]pyridazinone derivatives were synthesized. Kinase inhibition, cell proliferation, and whole blood stability assays were performed, allowing us to explore structure−activity relationship and to gain understanding of the structural requirements to modulate covalent inhibitors’ selectivity and reactivity. Compound 10h displayed highly potent antitumor efficacy in the NCI-H1581 xenograft model. [Display omitted]